Last reviewed · How we verify
rAd26-S
At a glance
| Generic name | rAd26-S |
|---|---|
| Also known as | Gam-COVID-Vac combined vector vaccine, Sputnik V, Gam-COVID-Vac combined vector vaccine (Component I) |
| Sponsor | R-Pharm |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan
- Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) (PHASE1, PHASE2)
- Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 (PHASE1, PHASE2)
- Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention (PHASE2)
- Study of Gam-COVID-Vac in Adolescents (PHASE2, PHASE3)
- Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. (PHASE2)
- Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (PHASE2)
- Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rAd26-S CI brief — competitive landscape report
- rAd26-S updates RSS · CI watch RSS
- R-Pharm portfolio CI